Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Reductive Amination . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101575321A details a nickel-catalyzed synthesis for trimetazidine, offering significant cost reduction and safety improvements over palladium or hydride methods for API intermediates.
Novel synthesis route for 3 6-diazabicyclo octane derivatives improves solubility and offers cost reduction in API manufacturing for global supply chains.
Patent CN116514666A reveals a safer bromhexine hydrochloride synthesis. Achieve cost reduction and high purity for pharmaceutical intermediates manufacturing.
Patent CN114573500A details a safer Fmoc-based synthesis for lefenacin intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN108003141A reveals a safer alfuzosin route. Achieve cost reduction in pharmaceutical intermediates manufacturing with stable yields and scalable processes.
Patent CN120554281A reveals a safer synthesis route for HALS intermediates. Achieve cost reduction and supply chain reliability with this novel atmospheric pressure method.
Patent CN114349648A details a one-step ruthenium-catalyzed reductive amination for high-purity chiral amines, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN103224963B reveals marine strain catalysis for high-purity chiral amines. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN101104609B discloses a mild reductive amination route for Solanesyl polyamine derivatives, offering high yields and scalable production for oncology drug discovery.
Novel non-hydrogenation route for Tamsulosin HCl. Eliminates heavy metals in step 1, ensuring high purity and safety for API manufacturing.
Novel S1P1 modulator synthesis via Mitsunobu reaction. Mild conditions, high selectivity. Reliable pharmaceutical intermediates supplier for IPF drug development.
Patent CN103276025A details a high-purity enzymatic route for L-heterocyclic amino acids, offering significant cost and supply chain advantages for API manufacturing.
Patent CN104945345A details low-cost benzoin route for chiral morpholine synthesis offering significant supply chain stability and cost advantages for global buyers.
Novel reductive amination process for sitagliptin intermediates eliminates precious metals, enhancing purity and supply chain reliability for global pharmaceutical manufacturing partners.
Patent CN101654416A details a scalable synthesis for anticancer intermediates, offering improved yields and safer processing compared to traditional nitro-reduction methods.
Patent CN110577941B reveals mutated enzymes for high-purity chiral amine synthesis, offering cost reduction in pharmaceutical intermediate manufacturing via biocatalysis.
Patent CN1622944A details a safer reductive amination route for chroman derivatives, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Novel Pictet-Spengler route from furfural reduces cost and complexity for pharmaceutical intermediates manufacturing.
Patent CN1206202C details a novel diamine manufacturing method suppressing N-alkyl impurities. Achieve high yield and cost reduction in fine chemical intermediates manufacturing.
Patent CN109824640B discloses a cost-effective 3-step synthesis of coumarin-based BRD4 inhibitors, offering reliable supply chain solutions for oncology drug development.